BioCentury
ARTICLE | Company News

Celgene gets option to acquire Lycera

June 10, 2015 1:51 AM UTC

Celgene Corp. (NASDAQ:CELG) obtained an exclusive option to license ex vivo applications of RAR-related orphan receptor C ( RORC; RORgamma) agonists from Lycera Corp. (Ann Arbor, Mich.), and a separate option to acquire the company outright.

Lycera is developing modulators of RORgamma, Rho-associated coiled-coil containing protein kinase 2 ( ROCK2), ATPase and histone deacetylase 6 ( HDAC6) to treat autoimmune diseases and cancer. Its lead program is LYC-30937, an oral gut-directed ATPase modulator in Phase I testing to treat inflammatory bowel disease (IBD). ...